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Abstract Candida tropicalis has emerged as the
third most prevalent fungal pathogens and its ability to
form biofilms has been considered one of the most
important virulence factors, since biofilms represent
high tolerance to antifungal agents. However, the
mechanisms of C. tropicalis biofilm resistance to
antifungals remain poorly understood. Thus, the main
aim of this work was to infer about the effect of
voriconazole on the formation and control of C.
tropicalis biofilms and disclose its relationship with
ERG genes’ expression. Planktonic cells tolerance of
several C. tropicalis clinical isolates to voriconazole
was determined through of antifungal susceptibility
test, and the effect of this azole against C. tropicalis
biofilm formation and pre-formed biofilms was eval-
uated by cultivable cells determination and total
biomass quantification. ERG genes expression was
analyzed by quantitative real-time polymerase chain
reaction. This work showed that C. tropicalis resis-
tance to voriconazole is strain dependent and that
voriconazole was able to partially control biofilm
formation, but was unable to eradicate C. tropicalis
pre-formed biofilms. Moreover, C. tropicalis biofilms
resistance to voriconazole seems to be associated with
alterations of sterol content in the cell membrane,
resulting in ERG genes overexpression. Voriconazole
is unable to control C. tropicalis biofilms, and the
overexpression of ERG genes is a possible mechanism
of biofilm resistance.
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Introduction
Invasive fungal infections, such as candidiasis, repre-
sent a public health problem of major importance,
since these infections are among the leading causes of
patients’ morbidity and mortality [1–3]. The members
of the genus Candida are the most frequently recov-
ered from human fungal infections and are of partic-
ular importance in patients undergoing treatment for
cancer, organ transplantation or receiving broad-
spectrum antibiotics or antifungal drugs [4]. This type
of infection has emerged due to the rise of the elderly
population, to a high number of immunocompromised
patients and to a more widespread use of indwelling
medical devices [1, 5–7].
Candida albicans is the main cause of candidiasis
and is responsible for the majority of mucosal and
systemic infections [2, 4, 7]. However, in parallel with
the overall increase in fungal infections, it has been
observed that infections caused by non-Candida
T. Fernandes  S. Silva (&)  M. Henriques
Laborato´rio de Investigac¸a˜o em Biofilmes Rosa´rio
Oliveira (LIBRO), Centre of Biological Engineering
(CEB), University of Minho, Campus de Gualtar,
4710-057 Braga, Portugal
e-mail: soniasilva@deb.uminho.pt
123
Mycopathologia (2016) 181:643–651
DOI 10.1007/s11046-016-0023-6
albicans Candida (NCAC) species, namely Candida
tropicalis, are also emerging [2, 8, 9]. Indeed, C.
tropicalis has been reported as an important causative
agent of the bloodstream and urinary tract infections in
hospitalized patients [2]. This increased incidence of
C. tropicalismay be attributed to its biofilm formation
capability [2, 9]. Biofilms are known as surface-
associated communities of microorganisms embedded
in an extracellular matrix (ECM), which may promote
infection and persistence in the host [1, 7, 10, 11].
Biofilms confer significant resistance to antifungal
therapy and host immune responses, by limiting the
penetration of substances through the ECM [1, 4, 12].
Moreover, Candida resistance to antifungal agents has
been associated with alterations of sterol content in
cell membrane, which should generally cause a
defective ergosterol biosynthesis, resultant frommuta-
tions in the ergosterol synthesis-associated genes
(ERG genes) [13–15].
For many decades, one of the most used antifungal
agents, as a prophylactic or therapeutic response to
candidiasis, was fluconazole (Flu). However, due to
many Flu resistance case reported, another azole,
voriconazole (Vcz), was developed in order to combat
Candida infections [4].
Many previous studies have focused on C. tropi-
calis tolerance to Flu, whereas there is a lack of studies
concerned Vcz [11, 12, 16]. Thus, the main goal of this
work was to infer about the effects of Vcz on the
formation and control of C. tropicalis biofilms and
disclose its relationship with ERG genes’ expression.
Materials and Methods
Organisms and Growth Conditions
Three differentC. tropicalis clinical isolates were used
during this work: one oral strain (AG1) isolated from a
patient of the Clinic Dentistry, Congregados, Braga,
Portugal; one urinary tract strain (519468) recovered
from a patient of the Hospital of S. Marcos, Braga,
Portugal; and one vaginal strain (12) belonging to
archive collection of the University of Maringa´,
Brazil. The strains identification of all isolates was
confirmed using CHROMagar Candida medium
(CHROMagar, France) and by polymerase chain
reaction (PCR)-based sequencing using specific pri-
mers (ITS1 and ITS4) against the 5.8S subunit gene
reference. Genomic deoxyribonucleic acid (DNA)
was extracted following previously described proce-
dures [17]. The PCR products were sequenced using
the ABI-PRISM Big Dye terminator cycle sequencing
kit (PerkinElmer, Applied Biosystems, Warrington,
UK). For all experiments, C. tropicalis strains were
subcultured on Sabouraud dextrose agar medium
(SDA; Merck, Germany) for 48 h at 37 C.
Antifungal Susceptibility Tests
Minimum inhibitory concentrations (MICs) for Vori-
conazole (Vcz; Pfizer, New York, USA) were deter-
mined, using the microdilution method, in accordance
with the guidelines of the Clinical and Laboratory
Standards Institute (CLSI) [18]. Vcz was tested in
concentrations of 0.5, 0.75, 1, 2, 3, 4, 6 and 10 mg/L. To
confirm the MICs values, the cell suspension of each
strain was recovered to a new well and serial dilutions
were plated in SDA at 37 C. After 48 h of incubation,
the total colony-forming units (CFUs) were determined
and the results presented as Log10 CFUs per milliliter
(Log10CFUs/mL). Assessments of the response profiles
with antifungal agent were performed in triplicate and
on three different occasions.
Biofilm Formation
Biofilm formation was performed as described previ-
ously by Silva et al. [1]. An inoculum of each yeast,
obtained fromSDAplates,was resuspended in 30 mLof
Sabouraud dextrose broth medium (SDB; Merck, Ger-
many) and incubated for 16–18 h at 37 C, under
agitation at 120 rpm. Then, cells were harvested by
centrifugation at 5000g, for 10 min at 4 C and washed
twice in phosphate buffer saline (PBS), pH 7.0, 0.1 M.
The cell pelletswere resuspended inPBSand the cellular
density adjusted to 2 9 105 cells/mL in Roswell Park
Memorial Institute 1640 medium (RPMI; Sigma, St.
Louis, USA) using a Neubauer counting chamber, to be
used in each experiment. The experimentswere repeated
in triplicate on three different occasions.
Voriconazole Effect on Biofilms
In order to study the effect of Vcz on biofilm
formation, different concentrations of antifungal agent
(5, 10, 50 and 100 mg/L) were prepared in RPMI 1640
medium and added at the beginning of the process of
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biofilm formation. The different concentrations of Vcz
used were selected in accordance with MICs previ-
ously determined. For that, 100 lL of each Candida
suspension containing 2 9 105 cells/mL and 100 lL
of antifungal agent were added to the respective
96-well microplates (Orange Scientific, Braine-l’
Alleud, Belgium). The microplates were incubated
for 48 h at 37 C and at 120 rpm, the same period of
the treatment applied during planktonic cells assays.
In order to infer about the effect of Vcz against C.
tropicalis pre-formed biofilms, biofilms were previ-
ously formed during 24 h at 37 C and at 120 rpm, in
RPMI 1640 medium. A volume of 100 lL of each
Candida suspension was added to the respective
96-well microplates containing 100 lL of RPMI
1640 medium. After this, the medium was aspirated
and different concentrations of Vcz (10, 50, 100 and
200 mg/L) prepared in RPMI 1640, were added to the
specific wells to treat the pre-formed biofilms and
incubated for additional 48 h at 37 C and at 120 rpm.
Controls were performed with Candida cells without
antifungal agent.
Biofilm Analyses
Biofilm Biomass Quantification
Biofilm total biomass was quantified by crystal violet
(CV) staining [1]. For that, after biofilm formation the
medium was totally aspirated and non-adherent cells
were removed by washing once with 200 lL of PBS.
The biofilm was fixed with 200 lL of methanol
(100 % v/v), which was removed after 15 min of
contact. The microplates were allowed to dry at room
temperature, and 200 lL of CV (1 % v/v) was added
to each well and incubated for 5 min. The wells were
then gently washed twice with 200 lL of sterile ultra-
pure water, and 200 lL of acetic acid (33 % v/v) was
added to release and dissolve the stain. The absor-
bance of the obtained solution was read in triplicate in
a microplate reader at 570 nm. The results were
presented as absorbance per unit area (Abs570nm/cm
2).
Biofilm Cultivable Cells Quantification
The number of cultivable biofilm’s cells was determined
by the enumeration of CFUs. For this, the medium was
aspirated and the biofilms washed once with 200 lL of
PBS to remove non-adherent cells. Then, the biofilm
was scraped from the 96-well microplates and the
suspensions were vigorously vortexed for 2 min to
disaggregate cells from the matrix [7]. Serial tenfold
dilution in PBS was plated in SDA and incubated at
37 C for 24 h. The results were presented as the total of
CFUs per unit area (log10 CFUs/cm
2).
Gene Expression Analysis
Gene Selection and Primers Design for Quantitative
Real-Time PCR
Five genes (ERG1, ERG3, ERG6, ERG9 and ERG11)
were selected to study their expression in biofilm cells,
in the presence and absence of Vcz. ACT1 gene was
selected as a reference Candida housekeeping gene
[19]. The gene sequences of interest were obtained
from Candida Genome Database (CGD) and the
primers for quantitative real-time PCR (qRT-PCR)
were designed using Primer 3 (http://simgene.com/
Primer3) Web-based software (Table 1). In order to
verify the specificity of each primer pair for its cor-
responding target gene, PCR products were first
amplified from C. tropicalis strains genomic DNA.
Moreover, genomic DNA was used to infer about the
primer efficiency and to determine the temperature of
melting (Tm).
Biofilm Cells Preparation
Biofilms were pre-formed in 24-well microplates with
a cellular density adjusted to 1 9 105 cells/mL in
RPMI 1640 medium, using a Neubauer counting
chamber. After 24 h, 1 mL of Vcz (at 100 mg/L) was
added to each well and the plate incubated at 37 C for
additional 48 h at 120 rpm. After this, the medium
was aspirated and non-adherent cells were removed by
washing twice with 1 mL of PBS, pH 7.0, 0.1 M.
Then, the biofilms were scraped from the 24-well
microplates, resuspended with 1 mL of PBS, and the
suspensions were vigorously vortexed for 2 min to
disaggregate cells from the matrix. Cells were har-
vested by centrifugation at 5000g for 10 min at 4 C.
RNA Extraction
Ribonucleic acid (RNA) extraction was performed
using E.Z.N.A. Total RNA Kit I (Omega Bio-Tek,
Norcross, USA). Prior to RNA extraction, the lysis
Mycopathologia (2016) 181:643–651 645
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buffer was prepared adding 1 % of b-mercap-
toethanol. Then, 600 lL of lysis buffer and glass
beads (425–600 lm diameter) were added to each
pellet. These mixes were homogenized thrice for 30 s
using a MP Biomedicals FastPrepTM-24 Instrument
(Thermo Fisher Scientific, Rockford, USA). After
cells disruption, the E.Z.N.A. Total RNA Kit I was
used for total RNA extraction according to the
manufacturer’s recommended protocol. To avoid
potential DNA contamination, samples were treated
with RNase-free DNase I. The RNA extraction was
performed in three different independents assays.
Synthesis of cDNA
To synthesize the complementary DNA (cDNA), the
High Capacity cDNA Reverse Transcription Kit (Life
Technologies, Carlsbad, USA) was used according to
the manufacturer’s instructions. For each sample,
10 lL of the extracted RNA of defined concentration
was used at a final volume of 20 lL of reaction, which
was completed with the remaining components of the
mastermix. cDNA synthesis was performed firstly for
10 min at 25 C and then for 1 h at 37 C. The
reaction was stopped by heating for 5 min at 85 C.
Quantitative Real-Time PCR
The qRT-PCR (CF X96 Real-Time PCR System; Bio-
Rad, Berkeley, USA) was used to determine the
relative levels of ERG1, ERG3, ERG6, ERG9 and
ERG11 messenger RNA (mRNA) transcripts in the
RNA samples, using ACT1 as reference Candida
housekeeping gene. Each reactionmixture consisted of
a working concentration of SsoFast EvaGreen Super-
mix (Bio-Rad, Berkeley, USA), 10 lM forward and
reverse primers, and 4 lL cDNA, in a final reaction
volume of 20 lL. Negative controls (water), as well as
non-transcriptase reverse (NRT) RNA controls, were
included in each run. The relative quantification of
genes expression was performed by the DCt method
[20], which was normalized to the housekeeping gene
(Ct average = 21.86 ± 0.84). Each reaction was per-
formed in triplicate, and mean values of relative
expression were determined for each gene.
Statistical Analysis
Statistical analysis was performed using GraphPad
Prism 6 software for Windows. The results were
compared using a two-way ANOVA with the Bonfer-
roni’s multiple comparisons test. The variation factors
assessed were always between the absence and
presence of Vcz. All tests were performed with a
95 % confidence level.
Results
Candida tropicalis Voriconazole Minimum
Inhibitory Concentrations
MICs of C. tropicalis were determined for Vcz using
the microdilution method and CFU counts (Table 2).
Table 1 Primers used for qRT-PCR, the respective melting temperature and product size
Genes Primers Sequences Melting temperature (C) Product size (bp)
ACT1 Forward GACCGAAGCTCCAATGAATC 57 181
Reverse AATTGGGACAACGTGGGTAA
ERG1 Forward GAGTTCGTGGTGTTGCTTTC 56 100
Reverse GTAACGGTTGCTTCAACAGC
ERG3 Forward GCAACTAGAGCCATTCCAGT 57 194
Reverse GGCCAATGTAACCATCTGTG
ERG6 Forward GAAACCAGGTGGTGTCTTTG 57 108
Reverse CCATCACCAACTTCGATACC
ERG9 Forward ACCATAAGTCACACCCAAGG 56 130
Reverse TCCGGAACAGTGGTCATAGT
ERG11 Forward CCAAGGCTAGTGCTGTTTCT 58 111
Reverse TGTGTCTACCACCACCGAAT
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The results revealed that C. tropicalis AG1 and 12
([10 mg/L) were resistant to Vcz according to the
MIC breakpoint from CLSI ([1 mg/L; C. tropicalis
ATCC 750) [18] and that C. tropicalis 519468 was
sensible with the lowest value of MIC (0.75–1 mg/L).
Effect of the Voriconazole on Candida tropicalis
Biofilms
Influence of Antifungal Agent on Biofilm Formation
In order to determine whether Vcz could prevent C.
tropicalis biofilm formation, biofilms were formed
during 48 h in the presence of different concentrations
of antifungal agent (Fig. 1). The data showed that all
Vcz concentrations were able to cause a significant
reduction in the number of cultivable cells compara-
tively to the control (p\ 0.0001). The same results
were obtained in terms of the total biomass reduction
(p\ 0.0001), however, in lower extension for the
clinical isolate C. tropicalisAG1 (p\ 0.0001 only for
50 and 100 mg/L of Vcz).
Influence of Antifungal Agent on Pre-formed Biofilms
To determine the effect of Vcz on pre-formed C.
tropicalis biofilms, 24-h-old biofilms were treated
during 48 h with different concentrations of antifungal
agent (Fig. 2). The results revealed that Vcz was
unable to reduce C. tropicalis pre-formed biofilms,
either in terms of the number of cultivable cells
(Fig. 2a) and total biomass (Fig. 2b). Moreover, it was
possible to observe for C. tropicalis 12 biofilms a
significant increase in terms of total biomass at all Vcz
concentrations (p\ 0.0001 at concentrations of 10, 50
and 100 mg/L and p\ 0.05 at concentrations of
200 mg/L). The total biomass also increased for C.
tropicalis 519468, however, only for the lowest
concentration of Vcz tested (10 mg/L) (p\ 0.01)
(Fig. 2b).
Effect of the Voriconazole on ERG Genes
Expression
Figure 3 presents the mean n-fold expression levels of
ERG1, ERG3, ERG6, ERG9 and ERG11 genes of the
C. tropicalis cells (from pre-formed biofilms) treated
with Vcz (100 mg/L), in comparison with the control
(absence of antifungal agent). This concentration of
Table 2 Candida tropicalis minimum inhibitory concentra-
tions obtained for voriconazole
Candida tropicalis
strains
Minimum inhibitory
concentrations (mg/L)
AG1 [10
12 [10
519468 0.75–1
Fig. 1 Effect of voriconazole on Candida tropicalis biofilm
formation after 48 h. a Mean values of the logarithm of CFUs
normalized by unit of area (log10 CFU/cm
2); b mean values
of the absorbance at 570 nm normalized by unit of area
(Abs570nm/cm
2). Error bars indicate the standard deviation.
Statistically different compared to respective control. **, ***
and ****correspond to p\ 0.01, p\ 0.001 and p\ 0.0001,
respectively
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Vcz was selected once the main aim was to disclose
the effect of the ERG genes on C. tropicalis biofilms
resistance to azole.
An overexpression of all ERG genes was evident
for all C. tropicalis biofilm cells treated with Vcz
(Fig. 3), although differences were observed depend-
ing on the strains and the ERG gene. ERG6 presented
the highest levels of expression for all strains
(Fig. 3c), and ERG1 (Fig. 3a) and ERG9 (Fig. 3d)
the lower levels for biofilm cells treated with Vcz. It
should be noted that, in the presence of Vcz (Fig. 3),
C. tropicalis AG1 biofilm cells showed the highest
expression for all ERG genes with less significant
differences for the other two strains.
Discussion
The main aim of this study was to determine the effect
of the Vcz on C. tropicalis biofilms and to disclose its
relationship with the ERG genes expression, and thus
deepen the knowledge regarding C. tropicalis biofilms
resistance mechanisms.
To reach the goal of this study, antifungal suscep-
tibility tests were performed according to CLSI
guidelines. Although the agent tested belong to the
azoles’ class, Vcz was selected due to its more recent
use, which is related to a better efficacy in the combat
of candidiasis and consequent lower resistance than
other azoles [4]. So, as expected, not all clinical
isolates were resistant to Vcz with MIC values strain
dependent (Table 2). These differences highlight the
strain susceptibility variations resultant from the
different origins of the clinical isolates, which were
recovered from patients submitted to different thera-
pies [4, 8, 21, 22].
As it is known, biofilms have been considered the
most prevalent growth form of microorganisms in
natural environments [4, 23, 24]. Biofilms present a
high versatility in adapting to a variety of different
habitats, being described as surface-associated com-
munities of microorganisms embedded within an
extracellular matrix [1, 4, 7, 10]. All C. tropicalis
clinical isolates assayed were able to form biofilms
with higher resistant to Vcz than their planktonic cells,
which is in agreement with other studies [4, 22, 25].
Additionally, this work revealed that Vcz possessed a
significant effect on C. tropicalis biofilms’ formation,
as evidenced by the significant reductions in the
number of cultivable cells and in total biomass values
(Fig. 1), but without effect on pre-formed biofilms
(Fig. 2). On the other hand, even the highest concen-
tration of Vcz was unable to reduce/destroy C.
tropicalis pre-formed biofilms (Fig. 2). It should also
be emphasized that even the lowest concentration
tested of Vcz (5 mg/L) was able to reduce the biofilm
(Fig. 1), what is a very important issue regarding
cytotoxicity and therefore patient’s safety. As is now,
pre-formed biofilms are mature biofilms, which sub-
sequently possesses a complex extracellular matrix,
Fig. 2 Effect of voriconazole against 24 h pre-formedCandida
tropicalis biofilms during 48 h. a Mean values of the logarithm
of CFUs normalized by unit of area (log10 CFU/cm
2); b mean
values of the absorbance at 570 nm normalized by unit of area
(Abs570nm/cm
2). Error bars indicate the standard deviation.
Statistically different compared to respective control. *, **, ***
and ****correspond to p\ 0.05, p\ 0.01, p\ 0.001 and
p\ 0.0001, respectively
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that difficult the penetration of agents, presenting
higher resistance to antifungals [4, 23, 26, 27]. Inter-
estingly, it was observed an increase in total biomass
when pre-formed biofilms were treated with interme-
diate concentrations of antifungal agent (Fig. 2b).
This phenomenon is probably due to a response of C.
tropicalis biofilm cells to the stress caused by the
presence of the agent, which lead to an expansion of
the biofilm matrices’ production.
It is known that the antifungal agents from the azole
class, with fungistatic activity, inhibit the biosynthesis
of ergosterol by interfering with the fungal enzyme,
lanosterol demethylase, which is a key enzyme in the
biosynthesis of ergosterol [4, 23]. Several molecular
mechanisms of azole antifungals’ resistance have been
reported for other Candida species, including alter-
ation in the chemical structure of the demethylase
enzyme, removal of the azole from the cell by
multidrug transporter pumps and compensation by
other sterol synthesis enzymes in membrane biosyn-
thesis [23]. Despite some information related to other
Candida species [13, 22, 23, 28], there is a lack of
information concerning the involvement of well-
known mechanisms of Vcz resistance in C. tropicalis.
Thus, to disclose the effective role of expression of
ERG genes (ERG1, ERG3, ERG6, ERG9 and ERG11)
on biofilms’ resistance, their expression was measured
in C. tropicalis biofilm cells treated with of Vcz, by
qRT-PCR. This work was demonstrative that the
expression of all ERG genes increased for biofilm cells
treated with Vcz (Fig. 3). Thus, it can be concluded
that the resistance ofC. tropicalis biofilm cells to azole
appears to be related to overexpression in ERG11
gene, possibly due to qualitative modifications in
enzyme lanosterol 14a-demethylase that convert
lanosterol to ergosterol, leading to depletion of the
sterol of cell membrane due to the inhibition of the
biosynthesis of ergosterol. Moreover, ERG6 gene was
also over expressed in the presence of Vcz (Fig. 3c).
ERG6 gene is described as required for a normal
bFig. 3 Effect of voriconazole on values of n-fold expression
levels of ERG1 (a), ERG3 (b), ERG6 (c), ERG9 (d) and ERG11
(e) genes in pre-formed Candida tropicalis biofilms. Biofilms
were formed during 24 h and treated with 100 mg/L of
voriconazole during 48 h. Comparisons were made with biofilm
cells growth in the absence of antifungal. Error bars indicate the
SDs. *, **, *** and **** correspond to p\ 0.05, p\ 0.01,
p\ 0.001 and p\ 0.0001, respectively
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membrane function and is localized after the ERG11
gene in ergosterol biosynthesis cascade. Thus, it can
be speculated that after qualitative modifications in
enzyme lanosterol 14a-demethylase, caused by Vcz
due to the overexpression in ERG11 gene, it could be
reflected in an overexpression of ERG6 gene and thus
can affect the normal membrane function [4]. In
contrast, the genes with lowest expression levels were
the ERG1 (Fig. 3a) and the ERG9 (Fig. 3d). It should
be pointed out that ERG9 and ERG1 appear before the
ERG11 gene in ergosterol biosynthesis, thus seeming
to be possible that its response assumes less impor-
tance than from the other genes, in C. tropicalis
biofilm cells resistance to Vcz. Mature C. tropicalis
biofilms are constitutes by several layers of cells that
make impossible the antifungal agents reach all cells
and this may be an explanation for the absence
statically differences between C. tropicalis 12 and
519468 levels of ERG genes expression.
Conclusions
In conclusion, this study confirmed that the pattern of
resistance of C. tropicalis planktonic cells to Vcz is
strain dependent. Moreover, it was also demonstrated
that Vcz was able to control partly C. tropicalis
biofilm formation but unable of eradicating C. trop-
icalis pre-formed biofilms. In addition, this work
revealed for the first instance that ERG genes could be
implicated in the mechanisms of C. tropicalis
biofilm’s cells resistance to Vcz.
Acknowledgments The authors thank the FCT for the Strategic
Project of the UID/BIO/04469/2013 unit, FCT and European
Union funds (FEDER/COMPETE) for the project RECI/BBB-
EBI/0179/2012 (FCOMP-01-0124-FEDER-027462). We also
would like to acknowledge Pfizer, S.A. for the kindly donation
of voriconazole.
References
1. Silva S, Henriques M, Martins A, Oliveira R, Williams D,
Azeredo J. Biofilms of non-Candida albicans Candida
species: quantification, structure and matrix composition.
Med Mycol. 2009;47:681–9.
2. Negri M, Silva S, Henriques M, Oliveira R. Insights into
Candida tropicalis nosocomial infections and virulence
factors. Eur J Clin Microbiol Infect Dis. 2012;31:1399–412.
3. Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal
infections. Clin Microbiol Rev. 1996;9:499–511.
4. Silva S, Negri M, Henriques M, Oliveira R, Williams DW,
Azeredo J. Candida glabrata, Candida parapsilosis and Can-
dida tropicalis: biology, epidemiology, pathogenicity and
antifungal resistance. FEMSMicrobiol Rev. 2012;36:288–305.
5. Kojic EM, Darouiche RO. Candida infections of medical
devices. Clin Microbiol Rev. 2004;17:255–67.
6. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida
species infections in critically ill non-immunosuppressed
patients. Lancet Infect Dis. 2003;3:685–702.
7. Silva S, Henriques M, Oliveira R, Williams D, Azeredo J.
In vitro biofilm activity of non-Candida albicans Candida
species. Curr Microbiol. 2010;61:534–40.
8. NegriM,MartinsM, HenriquesM, Svidzinski TIE, Azeredo
J, Oliveira R. Examination of potential virulence factors of
Candida tropicalis clinical isolates from hospitalized
patients. Mycopathologia. 2010;169:175–82.
9. Mun˜oz P, Giannella M, Fanciulli C, Guinea J, Valerio M,
Rojas L, et al.Candida tropicalis fungaemia: incidence, risk
factors and mortality in a general hospital. Clin Microbiol
Infect. 2011;17:1538–45.
10. Douglas LJ. Candida biofilms and their role in infection.
Trends Microbiol. 2003;11:30–6.
11. Bizerra FC, Nakamura CV, Poersch C, Svidzinski TIE,
Quesada RMB, Goldenberg S, et al. Characteristics of
biofilm formation by Candida tropicalis and antifungal
resistance. FEMS Yeast Res. 2008;8:442–50.
12. Al-Fattani MA, Douglas LJ. Biofilm matrix of Candida
albicans and Candida tropicalis: chemical composition and
role in drug resistance. J Med Microbiol. 2006;55:999–1008.
13. Vandeputte P, Tronchin G, Berge`s T, Hennequin C, Cha-
basse D, Bouchara J-P. Reduced susceptibility to polyenes
associated with a missense mutation in the ERG6 gene in a
clinical isolate of Candida glabrata with pseudohyphal
growth. Antimicrob Agents Chemother. 2007;51:982–90.
14. Mishra NN, Prasad T, Sharma N, Payasi A, Prasad R, Gupta
DK, et al. Pathogenicity and drug resistance in Candida
albicans and other yeast species. Acta Microbiol Immunol
Hung. 2007;54:201–35.
15. Baillie GS, Douglas LJ. Effect of growth rate on resistance
of Candida albicans biofilms to antifungal agents. Antimi-
crob Agents Chemother. 1998;42:1900–5.
16. Kothavade RJ, Kura MM, Valand AG, Panthaki MH.
Candida tropicalis: its prevalence, pathogenicity and
increasing resistance to fluconazole. J Med Microbiol.
2010;59:873–80.
17. Williams DW, Wilson MJ, Lewis MAO, Potts AJC. Iden-
tification of Candida species by PCR and restriction frag-
ment length polymorphism analysis of intergenic spacer
regions of ribosomal DNA. J Clin Microbiol. 1995;33:
2476–9.
18. CLSI. Reference method for broth dilution antifungal sus-
ceptibility testing of yeasts; fourth informational supple-
ment. CLSI document M27-S4. Wayne: Clin. Lab. Stand.
Inst. (CLSI); 2012.
19. Silva S, Hooper SJ, Henriques M, Oliveira R, Azeredo J,
Williams DW. The role of secreted aspartyl proteinases in
Candida tropicalis invasion and damage of oral mucosa.
Clin Microbiol Infect. 2011;17:264–72.
20. Livak KJ, Schmittgen TD. Analysis of relative gene
expression data using Real-Time quantitative PCR and the
2(-Delta Delta C(T)) method. Methods. 2001;25:402–8.
650 Mycopathologia (2016) 181:643–651
123
21. De Luca C, Guglielminetti M, Ferrario A, Calabr M, Casari
E. Candidemia: species involved, virulence factors and
antimycotic susceptibility. New Microbiol. 2012;35:459–68.
22. Fonseca E, Silva S, Rodrigues CF, Alves CT, Azeredo J,
Henriques M. Effects of fluconazole on Candida glabrata
biofilms and its relationship with ABC transporter gene
expression. Biofouling. 2014;30:447–57.
23. Williams DW, Kuriyama T, Silva S, Malic S, Lewis MAO.
Candida biofilms and oral candidosis: treatment and pre-
vention. Periodontol. 2000;2011(55):250–65.
24. Silva S, Negri M, Henriques M, Oliveira R, Williams DW,
Azeredo J. Adherence and biofilm formation of non-Can-
dida albicans Candida species. Trends Microbiol. 2011;
19:241–7.
25. Kumamoto CA. Candida biofilms. Curr Opin Microbiol.
2002;5:608–11.
26. Hawser SP, Douglas LJ. Resistance of Candida albicans
biofilms to antifungal agents in vitro. Antimicrob Agents
Chemother. 1995;39:2128–31.
27. Fernandes T, Silva S, Henriques M. Candida tropicalis
biofilm’s matrix-involvement on its resistance to ampho-
tericin B. Diagn Microbiol Infect Dis. 2015;83:165–9.
28. Mukherjee PK, Chandra J, Kuhn DM, Ghannoum MA.
Mechanism of fluconazole resistance in Candida albicans
biofilms: phase-specific role of efflux pumps and membrane
sterols. Infect Immun. 2003;71:4333–40.
Mycopathologia (2016) 181:643–651 651
123
